BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/19/2017 8:03:00 AM | Browse: 306 | Download: 230
Publication Name World Journal of Hematology
Manuscript ID 29628
Country of Manuscript Source Turkey
Received
2016-08-23 10:05
Peer-Review Started
2016-08-24 19:13
To Make the First Decision
2016-10-20 08:29
Return for Revision
2016-10-20 15:51
Revised
2016-10-21 14:40
Second Decision
2016-12-21 08:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-01-03 15:10
Articles in Press
2017-01-03 15:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-01-09 08:45
Publish the Manuscript Online
2017-01-19 08:03
ISSN 2218-6204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Hematology
Manuscript type Frontier
Article Title Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience
Manuscript Source Invited Manuscript
All Author List Nur Soyer, Ayse Uysal, Murat Tombuloglu, Fahri Sahin, Guray Saydam and Filiz Vural
Funding Agency and Grant Number
Correspondence To Nur Soyer, MD, Department of Hema­tology, Ege University Medical Faculty, Ankara Blvd, Bornova, 35100 Izmir, Turkey. drakadnur@yahoo.com
Keywords Chronic myeloid leukemia; Allogeneic stem cell transplantation; Tyrosine kinase inhibitors; Graft <i>vs</i> host disease; Survival
Core Tip Tyrosine kinase inhibitors (TKIs) have changed the fatal outcomes of chronic myeloid leukemia (CML). Many studies showed that TKIs provided rapid response, few serious adverse event and impressive survival out-comes. Although, allogeneic stem cell transplantation (ASCT) is only curative treatment option for CML, since 1999, the numbers of ASCT have dropped. Currently, ASCT is offering for patients who are resistant or intolerant to at least one second generation TKI or for patients with blastic phase. Here, we present our center’s out-comes of ASCT for patients with CML and then, we discuss the place of ASCT in CML treatment in the TKIs era.
Publish Date 2017-01-19 08:03
Citation Soyer N, Uysal A, Tombuloglu M, Sahin F, Saydam G, Vural F. Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience. World J Hematol 2017; 6(1): 1-10
Url http://www.wjgnet.com/2218-6204/full/v6/i1/1.htm
DOI http://dx.doi.org/10.5315/wjh.v6.i1.1
Full Article (PDF) WJH-6-1.pdf
Full Article (Word) WJH-6-1.doc
Manuscript File 29628-Review.docx
Answering Reviewers 29628-Answering reviewers.pdf
Audio Core Tip 29628-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 29628-Conflict-of-interest statement.pdf
Copyright License Agreement 29628-Copyright assignment.pdf
Peer-review Report 29628-Peer-review(s).pdf
Scientific Misconduct Check 29628-Scientific misconduct check.pdf
Scientific Editor Work List 29628-Scientific editor work list.pdf